RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?

Key Takeaways RIGL shares have surged 59% in a year, far outpacing industry and market gains.Tavalisse remains the backbone, while oncology drugs steadily diversify revenue.Rigel guides for higher 2026 sales and positive net income amid competitive risks.Shares of Rigel Pharmaceuticals (RIGL) have surged 59% in the past year, significantly outperforming the industry’s 2% growth. The stock has also outperformed the sector and the S&P 500 during the same period, as shown in the chart below.RIGL Stock Outperfo ...